Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has named Michael Halstead as its new chief executive officer, effective immediately. The appointment comes at a pivotal time for the clinical-stage company as it advances its lead candidate, HLP003, through Phase 3 development and gears up for potential commercialization. Halstead, who previously served as president of Intra-Cellular Therapies, brings over 25 years of biopharmaceutical leadership experience, including overseeing the development and commercialization of CAPLYTA, a treatment for bipolar depression. He also played a key role in supporting pipeline expansion and helping guide the company’s $14.6 billion acquisition by Johnson & Johnson in 2025.
The leadership change is strategically timed. Helus Pharma has completed enrollment in the Phase 3 APPROACH trial for HLP003, with topline data expected in the fourth quarter of 2026. Simultaneously, the company is continuing enrollment in the EMBRACE pivotal study, another key trial for HLP003. Additionally, the company is advancing HLP004 for generalized anxiety disorder, which is currently in Phase 2 development.
Halstead’s appointment is significant for several reasons. His track record in taking a drug from late-stage development to commercial success is directly relevant to Helus Pharma’s current stage. CAPLYTA, which he helped commercialize, became a major revenue driver for Intra-Cellular Therapies, and his experience in navigating regulatory approvals and market launches will be invaluable as Helus Pharma prepares for potential FDA approval and market entry. Moreover, his involvement in the successful acquisition by Johnson & Johnson demonstrates his ability to manage complex corporate transactions, which could be a factor in Helus Pharma’s future strategic options.
The company’s focus on novel serotonergic agonists (NSAs) is part of a broader trend in mental health treatment, moving beyond traditional SSRIs to target neuroplasticity. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address major depressive disorder in patients who have not responded adequately to existing treatments. This designation also expedites the development and review process, which could accelerate the timeline to market.
The implications of this announcement are multi-faceted. For investors, the appointment of a proven leader may increase confidence in the company’s ability to execute its clinical and commercial plans. For patients, it signals that Helus Pharma is serious about bringing HLP003 to market, potentially offering a new option for those with treatment-resistant depression. For the broader industry, it highlights the growing interest in psychedelic-inspired therapies and their potential to transform mental health care.
As Helus Pharma moves forward, all eyes will be on the upcoming Phase 3 data readout. A positive result could position the company for a successful launch, and Halstead’s leadership will be central to that effort. The company’s ongoing work with HLP004 also adds to its pipeline strength, providing diversification beyond its lead candidate.
In summary, the appointment of Michael Halstead as CEO is a strategic move that aligns with Helus Pharma’s critical next steps. His experience in commercialization and corporate strategy will be instrumental as the company approaches a potential inflection point. With Phase 3 data on the horizon and a robust pipeline, Helus Pharma is positioning itself to make a significant impact in mental health treatment.
